ESGO/ISUOG/IOTA/ESGE Consensus Statement on preoperative diagnosis of ovarian tumors.

Liquid biopsy in ovarian cancer: recent advances on circulating tumor cells and circulating tumor DNA. 173 Demidov VN, Lipatenkova J, Vikhareva O, Van Holsbeke C, Timmerman D, Valentin L. Imaging of gynecological disease (2): clinical and ultrasound characteristics of Sertoli cell tumors, Sertoli-Leydig cell tumors and Leydig cell tumors. I The European Society of Gynaecological Oncology (ESGO), the International Society of Ultrasound in Obstetrics and Gynecology (ISUOG), the International Ovarian Tumour Analysis (IOTA) group and the European Society for Gynaecological Endoscopy (ESGE) jointly developed clinically relevant and evidence-based statements on the preoperative diagnosis of ovarian tumors, including imaging techniques, biomarkers and prediction models i . This multiclass prediction model is the first risk model to differentiate between benign and malignant tumors, whilst also offering subclassification of any malignancy into borderline tumors, Stage-I and Stage-II-IV primary cancers and secondary metastatic tumors. Positron emission tomography-computed tomography Positron emission tomography-computed tomography (PET-CT) may be useful in differentiating malignant from borderline or benign ovarian tumors, with the limitation that its diagnostic performance can be impacted negatively by certain tumor histological subtypes, due to the lower fluorodeoxyglucose uptake in clear-cell and mucinous invasive subtypes147-152. [Extracted from the article]